FRR Shares (Makes you Realise)

Equity

Home/ Are You A Trader/ Market Info/ Company Profile/ Smart Quotes

COMPANY PROFILE

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC

BSE9105.7571.95 (+0.8 %)

PREV CLOSE (Rs.) 9033.80

OPEN PRICE (Rs.) 9033.80

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 209

TODAY'S LOW / HIGH (Rs.)8970.00 9135.00

52 WK LOW / HIGH (Rs.)6222.35 10653.05

NSE9100.5055 (+0.61 %)

PREV CLOSE( Rs. ) 9045.50

OPEN PRICE (Rs.) 8960.50

BID PRICE (QTY) 9100.50 (44)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 10708

TODAY'S LOW / HIGH(Rs.) 8960.50 9147.00

52 WK LOW / HIGH (Rs.)6220 10691

More From Company Profile

Smart Quotes

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Trade Value (Rs. in Lacs)

18.89

Dividend Yield(%)

0.35

TTM EPS (Rs.)

73.34

P/E Ratio

124.15

Book Value (Rs.)

327.61

Face Value (Rs.)

MCap (Rs. in Mn)

227643.75

Price/Earning (TTM)

96.46

Price/Sales (TTM)

12.27

Price/Book (MRQ)

27.79

PAT Margin (%)

6.72

ROCE (%)

21.29

Incorporation Year : 11-07 1979

Management Info :

Shilpa Divekar Nirula - Chairman - Managing Director

Registered Office :

Address : Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring Road,
Bengaluru,
Karnataka-560045

Phone : 080 6774 8000

Email : comp.secy@astrazeneca.com

Website : www.astrazenecaindia.com/india

Registrars Details :

Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)

30, Ramana Residency,4th Cross, Sampige Road,Malleswaram,Bangalore

Listing : BSE, NSE

NEWS

08Aug AstraZeneca Pharma India trades higher
Astrazeneca Pharma India is currently trading at Rs. 8769.55, up by 41.0..

07Aug AstraZeneca Pharma India to launch Ecu
AstraZeneca Pharma India is all set to launch Eculizumab (Soliris) in Au..

01Aug Clarification On News Item Appearing
Please find the enclosed letter of the Company in relation to the captio..

Financials

	QTR Jun 25	ANNUAL 25
Net Profit	558.3	1157.4
Gross Profit	747	1563.6
Operating Profit	923.5	2946
Net Sales	5263.1	17162.9

Rs. in Millions

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Glenmark Pharma (BSE)

2116.25 (3.10%)

M.Cap (Rs. in Cr)59720.75

Gland Pharma (BSE)

1919.35 (2.72%)

M.Cap (Rs. in Cr)31622.52

Dr. Reddy's Lab (BSE)

1293.45 (3.45%)

M.Cap (Rs. in Cr)107952.28

Wockhardt (BSE)

1496.75 (2.54%)

M.Cap (Rs. in Cr)24321.02

Shareholding Pattern

	PROMOTERS	75%
	NON-INSTITUTION	17.42%
	MUTUAL FUNDS/UTI	4.33%
	FI/BANKS/INSURANCE	0.18%
	GOVERNMENT	0%
	FII	0%

Mf Holding

Scheme Name

Hold(%)

Samco Flexi Cap Fun...

5.47

Bandhan Innovation ...

3.70

Samco Active Moment...

3.30

Baroda BNP Paribas ...

2.30

Baroda BNP Paribas ...

2.03

Samco ELSS Tax Save...

1.94

DSP Nifty Smallcap2...

1.64

Attention Investors

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month, Issued in the interest of Investors.

Risk Disclosure on Derivatives | Smart ODR | Mandatory Display | KYC Validation Links

BSE / NSE SEBI Registration No. INZ000279232, Depository Participant SEBI Registration No. – IN DP CDSL 132-2015

Mutual funds - ARN No. 81648 , Investment Adviser SEBI Registration No. : INA000008668.

CLOSE X

Risk Disclosures On Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22

ASTRAZENECA PHARMA INDIA LTD.

Smart Quotes

Attention Investors

Download Client Registration Documents

Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language :

Filing complaints on SCORESEasy & quick

Risk Disclosures On Derivatives